

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

*Rule 4.7B*

## Appendix 4C

### Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Ltd (subject to Deed of Company Arrangement)

ABN

12 006 464 866

Quarter ended ("current quarter")

30 June 2002

#### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	140	446
1.2 Payments for		
(a) staff costs	(52)	(382)
(b) advertising and marketing	-	-
(c) research and development	(12)	(125)
(d) leased assets	-	-
(e) other working capital	(323)	(712)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	3	13
1.5 Interest and other costs of finance paid	(62)	(92)
1.6 Income taxes paid	-	-
1.7 Other (provide details if material)	-	-
<b>Net operating cash flows</b>	<b>(306)</b>	<b>(852)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (12months) \$A'000
1.8 Net operating cash flows (carried forward)	(306)	(852)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(81)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(3)	(21)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	162
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	18
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
<b>Net investing cash flows</b>	(3)	78
1.14 <b>Total operating and investing cash flows</b>	(309)	(774)
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	-	770
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	167	8
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other (provide details if material)	-	-
<b>Net financing cash flows</b>	167	778
<b>Net increase (decrease) in cash held</b>	(142)	4
1.21 Cash at beginning of quarter/year to date (Opening cash has been adjusted from previously reported as the cash balance included cash that was under the control of the administrator and not available to the company)	147	540 (539)
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 <b>Cash at end of quarter</b>	5	5

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	30
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	

**Non-cash financing and investing activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

In December 2001, Analytica Ltd acquired from Psiron Ltd its diagnostic business for \$1.6m. The funding for this purchase was through a loan from Psiron which is repayable over 8 years.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

**Financing facilities available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	1,600,000	1,600,000
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	5	147
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.22)</b>	<b>5</b>	<b>147</b>

**Acquisitions and disposals of business entities**

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity		Phytomed Laboratories Pty Ltd (Sept qtr) Biomatrix Pty Ltd (Sept qtr)
5.2 Place of incorporation or registration		Both in Victoria
5.3 Consideration for acquisition or disposal		-
5.4 Total net assets		Deficiency of net assets \$151,000
5.5 Nature of business		Manufacture and sale of Modern Chines Medicines

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

  
 (Company Secretary)

Date:

31/7/02

Print name:

BRYAN DULHUNTY

+ See chapter 19 for defined terms.